Peginterferon beta-1a 63 mcg in 0.5 mL (1) Auto-Injector / peginterferon beta-1a 94 mcg in 0.5 mL (1) Auto-Injector Pack
RxNorm 1649602
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1649602 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: peginterferon beta-1a 63 mcg in 0.5 mL (1) Auto-Injector / peginterferon beta-1a 94 mcg in 0.5 mL (1) Auto-Injector Pack.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
Prescribable Name (PSN):
Peginterferon beta-1a 63 mcg in 0.5 mL (1) Auto-Injector / peginterferon beta-1a 94 mcg in 0.5 mL (1) Auto-Injector Pack
(Atom ID: 8238440)
Generic Pack (GPCK):
{1 (0.5 mL peginterferon beta-1a 0.126 mg/ML Auto-Injector) / 1 (0.5 mL peginterferon beta-1a 0.188 mg/ML Auto-Injector) } Pack
(Atom ID: 7238527)
Patient Education
Peginterferon Beta-1a Injection
Peginterferon beta-1a injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including the following: clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours), relapsing-remitting forms (course of disease where symptoms flare up from time to time), or secondary progressive forms (course of disease where relapses occur more often). Peginterferon beta-1a injection is in a class of medications called immunomodulators. It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis.
[Learn More]
* Please review the disclaimer below.
